<DOC>
	<DOCNO>NCT00339183</DOCNO>
	<brief_summary>The purpose study evaluate treatment effect panitumumab plus FOLFIRI compare FOLFIRI alone second line therapy metastatic colorectal cancer .</brief_summary>
	<brief_title>Comparison Treatment Effect Chemotherapy With Panitumumab Chemotherapy Alone</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Man woman least 18 year old Diagnosis metastatic colorectal cancer ( mCRC ) One one chemotherapy regimen mCRC consist firstline 5FU base chemotherapy Radiologically document disease progression per modify Response Evaluation Criteria Solid Tumors ( RECIST ) criteria treatment within 6 month last dose firstline chemotherapy At least 1 unidimensionally measurable lesion least 20 mm per modify RECIST Eastern Cooperative Oncology Group ( ECOG ) status 0 , 1 , 2 Paraffinembedded tumor tissue primary tumor metastasis available central analysis Adequate hematologic , renal , hepatic function Negative pregnancy test within 72 hour enrollment Other protocolspecified criterion may apply History know presence central nervous system ( CNS ) metastases History another primary cancer within 5 year randomization Prior irinotecan therapy Prior antiepidermal growth factor receptor ( EGFr ) antibody therapy treatment small molecule EGFr inhibitor Any investigational agent therapy within 30 day randomization Known allergy hypersensitivity irinotecan , 5FU leucovorin History interstitial lung disease evidence interstitial lung disease baseline chest compute tomography ( CT ) scan Active inflammatory bowel disease bowel disease cause chronic diarrhea Known positive test human immunodefiency virus ( HIV ) , hepatitis C viris ( HCV ) , acute chronic active hepatitis B virus ( HBV ) Major surgery within 28 day randomization minor surgical procedure within 14 day randomization Pregnant breastfeeding Man woman childbearing potential consenting use adequate contraceptive method abstinence course study 6 month last study drug administration ( woman ) 1 month last study drug administration ( men ) Other protocolspecified criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>EGFr</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Amgen</keyword>
</DOC>